Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 3Genitourinary 3Head & Neck 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 618Head and Neck Neoplasms 599Nasopharyngeal Carcinoma 230Thyroid Neoplasms 148Oropharyngeal Neoplasms 104Carcinoma, Squamous Cell 90Salivary Gland Neoplasms 88Mouth Neoplasms 87Nasopharyngeal Neoplasms 79Recurrence 66Carcinoma, Non-Small-Cell Lung 66Laryngeal Neoplasms 60Neoplasm Metastasis 58Neoplasms 49Hypopharyngeal Neoplasms 45Thyroid Carcinoma, Anaplastic 42Thyroid Cancer, Papillary 42Melanoma 38Breast Neoplasms 36Lung Neoplasms 34Adenocarcinoma, Follicular 33Carcinoma 32Tongue Neoplasms 30Sarcoma 29Uterine Cervical Neoplasms 28Stomatitis 28Colorectal Neoplasms 28Carcinoma, Medullary 24Ovarian Neoplasms 23Esophageal Neoplasms 23

Interventions

Rogaratinib 1Drug Combinations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Acrocephalosyndactylia × Head & Neck × Clear all
NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Bayer

Phase 2 Completed
1 enrolled
BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡